The genetic testing
industry, all in one place.

Motley Fool's 2026 genomics stock picks reflect growing Wall Street confidence in sequencing, liquid biopsy, and precision medicine companies.

Singapore's NPM program publishes findings on translating population-scale genomic data into actionable healthcare practice.

Guardant Health surged 25% after FDA cleared the first combined genomic-epigenomic liquid biopsy panel, marking a major milestone for non-invasive cancer testing.

A cerebrospinal fluid DNA test shows promise for improving brain tumor diagnosis, offering a less invasive alternative to surgical biopsy.

Tempus AI has received FDA clearance for a pulmonary hypertension diagnostic tool, marking another regulatory milestone for the genomics-driven AI company.

Gene Solutions is pursuing a Hong Kong IPO to fund expansion, signaling growing investor appetite for genomics in Southeast Asia.

Regeneron wins FDA approval for the first neurosensory gene therapy, marking a landmark moment for genetic medicine and the broader testing ecosystem.

Advanced DNA testing technology is being applied to a 2005 Paulding County cold case, highlighting forensic genomics' growing investigative reach.